← BeOne Medicines overview

BeOne Medicines vs Regeneron Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

BeOne Medicines AG (6160.HK)

Q3 2026
▲3▼1

BeOne Q3: Pipeline Wins, US Investment, But Pricing Deal Looms

  • BRUKINSA Phase 3 Wins and Solid Tumor Progress BRUKINSA scored Phase 3 wins in CLL and mantle cell lymphoma, reinforcing its core status. Three solid-tumor programs advanced toward pivotal trials, prompting analyst price-target hikes.

    This point highlights the clinical and pipeline successes that drove positive sentiment and analyst upgrades.

  • US Manufacturing Investment and Strong Q2 Revenue BeOne invested $1 billion in U.S. manufacturing and reported Q2 revenue up 30% with raised guidance, signaling confidence in growth and supply chain expansion.

    This point captures the financial and operational investments that supported the stock's positive momentum.

  • FDA Approval and Positive Survival Data for TEVIMBRA/ZIIHERA The FDA approved TEVIMBRA plus ZIIHERA for HER2+ gastroesophageal cancer, and HERIZON-GEA-01 showed positive survival data, expanding treatment options.

    This point underscores regulatory and clinical milestones that open new market opportunities.

  • CEO Stock Sale and US Pricing Agreement The CEO sold $34.6 million in stock under a pre-set plan, though he retains over 50 million shares. A U.S. pricing agreement traded tariff relief for Medicaid discounts and lower prices, potentially pressuring future revenue.

    This point presents the main counterweights that could temper positive developments.

August 2026
▲3

BeOne's strong Q2, new drug approvals, and US pricing deal shape outlook

  • Q2 revenue jumps 30%, guidance raised BeOne reported Q2 revenue of $1.7 billion, up 30% from a year ago, with earnings per share up 144%. The company raised its full-year revenue and profit guidance and doubled free cash flow. This shows the business is growing strongly and has more money to invest in new drugs, which supports a higher stock price.

    This is the core financial update that directly boosts investor confidence and the stock's value.

  • FDA approves TEVIMBRA combo for HER2+ cancer The FDA approved BeOne's TEVIMBRA combined with ZIIHERA and chemotherapy for first-line HER2-positive gastroesophageal cancer. This is a new treatment option for a cancer affecting over 31,000 Americans yearly. The approval opens a new revenue stream and validates the company's research, pushing the stock up.

    A new regulatory approval directly expands the company's marketable products and future sales.

  • Positive Phase 3 survival data for ZIIHERA regimens BeOne announced positive topline results from the Phase 3 HERIZON-GEA-01 trial, showing ZIIHERA plus chemotherapy significantly improved overall survival in first-line HER2+ gastroesophageal adenocarcinoma. Longer follow-up for the TEVIMBRA plus ZIIHERA regimen also showed durable outcomes. Strong data increases confidence in the drug's commercial success.

    Strong clinical trial results support the drug's efficacy and potential for wider use, lifting the stock.

  • US pricing deal: tariff relief but price discounts BeOne signed a voluntary agreement with the US government to expand cancer drug access, including participation in the GENEROUS Model and Medicaid discounts, in exchange for exemption from Section 232 pharmaceutical tariffs. While this avoids costly tariffs and supports US manufacturing, it also means lower prices for some drugs, which could pressure future revenue.

    This is a major regulatory and pricing development that has both positive (tariff exemption) and negative (price cuts) implications for the stock.

Latest
▲3

BeOne's strong Q2, new drug approvals, and US pricing deal shape outlook

  • Q2 revenue jumps 30%, guidance raised BeOne reported Q2 revenue of $1.7 billion, up 30% from a year ago, with earnings per share up 144%. The company raised its full-year revenue and profit guidance and doubled free cash flow. This shows the business is growing strongly and has more money to invest in new drugs, which supports a higher stock price.

    This is the core financial update that directly boosts investor confidence and the stock's value.

  • FDA approves TEVIMBRA combo for HER2+ cancer The FDA approved BeOne's TEVIMBRA combined with ZIIHERA and chemotherapy for first-line HER2-positive gastroesophageal cancer. This is a new treatment option for a cancer affecting over 31,000 Americans yearly. The approval opens a new revenue stream and validates the company's research, pushing the stock up.

    A new regulatory approval directly expands the company's marketable products and future sales.

  • Positive Phase 3 survival data for ZIIHERA regimens BeOne announced positive topline results from the Phase 3 HERIZON-GEA-01 trial, showing ZIIHERA plus chemotherapy significantly improved overall survival in first-line HER2+ gastroesophageal adenocarcinoma. Longer follow-up for the TEVIMBRA plus ZIIHERA regimen also showed durable outcomes. Strong data increases confidence in the drug's commercial success.

    Strong clinical trial results support the drug's efficacy and potential for wider use, lifting the stock.

  • US pricing deal: tariff relief but price discounts BeOne signed a voluntary agreement with the US government to expand cancer drug access, including participation in the GENEROUS Model and Medicaid discounts, in exchange for exemption from Section 232 pharmaceutical tariffs. While this avoids costly tariffs and supports US manufacturing, it also means lower prices for some drugs, which could pressure future revenue.

    This is a major regulatory and pricing development that has both positive (tariff exemption) and negative (price cuts) implications for the stock.

July 2026
▲3

BeOne's pipeline and BRUKINSA data drive gains; CEO sale and US expansion in focus

  • BRUKINSA Phase 3 wins in two blood cancers Updated SEQUOIA data showed BRUKINSA kept 71.8% of CLL patients progression-free at 78 months versus 31% for standard chemo. Separately, the MANGROVE trial in frontline mantle cell lymphoma cut progression or death risk by 43%. These strengthen BRUKINSA as a foundational therapy and support future sales growth.

    Directly boosts confidence in the company's biggest selling drug and its expansion into new uses.

  • Three new cancer drugs advance toward pivotal trials At ASCO 2026, BeOne presented promising data for three solid-tumor programs: BGB-43395 for breast cancer, BG-C9074 for ovarian cancer, and BGB-B2033 for liver cancer. All target areas with high unmet need. Analysts called it an inflection point, raising price targets to as high as $436.

    Shows the company is building a broader pipeline beyond BRUKINSA, which could drive future revenue.

  • CEO sells $34.6 million in stock under pre-set plan CEO John Oyler sold 109,713 shares for $34.6 million under a trading plan adopted in March 2026. He still holds over 50 million shares, so the sale is a tiny fraction of his stake. Such sales can spook investors, but the pre-set nature and his large remaining holding soften the blow.

    A potential negative signal that is largely neutralized by the pre-planned nature and small size relative to his holdings.

  • BeOne invests $1 billion in U.S. manufacturing BeOne is expanding its New Jersey site with a $300 million addition, bringing total U.S. investment to over $1 billion. The new facility will make small-molecule drugs and add 120 jobs. This supports its pipeline of 35+ assets and may ease supply and regulatory risks.

    Strengthens domestic production capacity, which can support future sales and reduce reliance on overseas manufacturing.

▲3

BeOne's pipeline and BRUKINSA data drive gains; CEO sale and US expansion in focus

  • BRUKINSA Phase 3 wins in two blood cancers Updated SEQUOIA data showed BRUKINSA kept 71.8% of CLL patients progression-free at 78 months versus 31% for standard chemo. Separately, the MANGROVE trial in frontline mantle cell lymphoma cut progression or death risk by 43%. These strengthen BRUKINSA as a foundational therapy and support future sales growth.

    Directly boosts confidence in the company's biggest selling drug and its expansion into new uses.

  • Three new cancer drugs advance toward pivotal trials At ASCO 2026, BeOne presented promising data for three solid-tumor programs: BGB-43395 for breast cancer, BG-C9074 for ovarian cancer, and BGB-B2033 for liver cancer. All target areas with high unmet need. Analysts called it an inflection point, raising price targets to as high as $436.

    Shows the company is building a broader pipeline beyond BRUKINSA, which could drive future revenue.

  • CEO sells $34.6 million in stock under pre-set plan CEO John Oyler sold 109,713 shares for $34.6 million under a trading plan adopted in March 2026. He still holds over 50 million shares, so the sale is a tiny fraction of his stake. Such sales can spook investors, but the pre-set nature and his large remaining holding soften the blow.

    A potential negative signal that is largely neutralized by the pre-planned nature and small size relative to his holdings.

  • BeOne invests $1 billion in U.S. manufacturing BeOne is expanding its New Jersey site with a $300 million addition, bringing total U.S. investment to over $1 billion. The new facility will make small-molecule drugs and add 120 jobs. This supports its pipeline of 35+ assets and may ease supply and regulatory risks.

    Strengthens domestic production capacity, which can support future sales and reduce reliance on overseas manufacturing.

Regeneron Pharmaceuticals Inc (REGN)

Q3 2026
▲1▼1

Regeneron's Q3: Pipeline Wins, Melanoma Setback, Sanofi Deal

  • Q2 earnings beat with 17% revenue growth Regeneron's Q2 revenue rose 17% to $4.29 billion, beating estimates, driven by strong Dupixent and high-dose Eylea sales, while Sanofi repayment improved margins.

    Strong financial results directly boost investor confidence and the stock price.

  • Failed melanoma trial triggers lawsuits and $11B value loss A failed melanoma trial led to securities lawsuits and wiped out $11 billion in market value, highlighting pipeline execution risks and disappointing investors.

    This major setback significantly impacted Regeneron's market value and reputation.

  • Sanofi alliance expands with $1B upfront but Dupixent profit-sharing unchanged Sanofi's expanded alliance brought $1 billion upfront and up to $7 billion in milestones, but left Dupixent profit-sharing unchanged, causing shares to drop 4%.

    The deal has both positive financial aspects and negative implications for Dupixent economics.

September 2026
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Latest
▲3▼1

Regeneron's pipeline wins and Sanofi deal offset by Eylea competition

  • Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

    This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

  • Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

    A positive clinical readout in a major new market area is a key driver of future growth expectations.

  • Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

    Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

  • Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

    It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

August 2026
▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

▲3▼1

Regeneron beats on Dupixent/Eylea, wins rare-disease approval, faces lawsuit

  • Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

    This is the period's biggest positive fundamental driver of REGN's value.

  • Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

    It is a concrete capital event that improves future profitability.

  • FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

    A new FDA approval is a fresh product and pipeline milestone for REGN.

  • Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

    This is the main negative overhang on REGN this period.

July 2026
▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

▼2▲1

Regeneron's pipeline setbacks trigger lawsuits, but cemdisiran advances

  • Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

    This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

  • Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

    This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

  • Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

    This new analyst commentary underscores pipeline challenges that could pressure the stock.

Q2 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

June 2026
▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

▲3▼1

Regeneron advances new drugs as Dupixent soars and AbbVie threat looms

  • CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

    This is a new deal that adds to Regeneron's pipeline and potential future earnings.

  • Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

    Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

  • FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

    This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

  • AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

    This is a new competitive threat that could impact Regeneron's key product, Dupixent.

© 2026 MarketIVWhy